Asparia Glycomics, established in 2016 as a CIC biomaGUNE spin-off, originated from the Glycotechnology Laboratory led by Niels Reichardt and specializes in cutting-edge glycan analysis technology. It provides isotope-labeled standards, custom kits, software, and reagents for clinical diagnostics and biopharma quality control. Dedicated to improving the identification and quantification of glycan disease markers with greater accuracy and speed, it has achieved financial stability since 2020, earning recognition as a trusted biotech partner for academia and industry.

Hylezitek, established in 2022 and fully owned by CIC biomaGUNE, specializes in the provision of services for research, innovation and development in biomaterials. The company focuses on the development multimodal and longitudinal studies in the preclinical field, along with the development of applications in Preclinical Molecular and Functional Imaging and Nanomedicine, supporting cutting-edge advancements in these areas.

Taldeki, established in 2024 as a CIC biomaGUNE spin-off, originated from the Biomolecular Nanotechnology Lab led by Aitziber Cortajarena and specializes in hybrid technologies for biomolecular recognition. Its platform, based on Hybrid Mimetic Antigens, enables rapid and specific detection of multiple targets, including antibodies, antigens, proteins, cancer cells, and nanobodies. The technology uses engineered binding protein sequences and metal clusters as reporters (photoluminescent, catalytic, electroactive, magnetic). Taldeki’s solutions also include antibody detection and targeted MRI contrast agents for diverse biomolecule detection.